AR032152A1 - Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica - Google Patents
Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceuticaInfo
- Publication number
- AR032152A1 AR032152A1 ARP010101697A ARP010101697A AR032152A1 AR 032152 A1 AR032152 A1 AR 032152A1 AR P010101697 A ARP010101697 A AR P010101697A AR P010101697 A ARP010101697 A AR P010101697A AR 032152 A1 AR032152 A1 AR 032152A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- hypertension
- manufacture
- pharmaceutical composition
- therapeutic agent
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000003532 hypothyroidism Diseases 0.000 abstract 1
- 230000002989 hypothyroidism Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El uso de una combinacion de cuando menos dos componentes terapéuticos en combinacion seleccionados a partir del grupo que consiste en: (i) un antagonista del receptor AT1, o un antagonista del receptor AT1 combinado con un diurético, o en cada caso, una sal farmacéuticamente aceptable de los mismos, (ii) un inhibidor de HMG-Co-A reductasa o una sal farmacéuticamente aceptable del mismo, y (iii) un inhibidor de ACE o una sal farmacéuticamente aceptable del mismo; caracterizado porque es para la fabricacion de un medicamento para la prevencion, demora de progreso, o tratamiento de una enfermedad o condicion seleccionada a partir del grupo que consiste en hiperlipidemia y dislipidemia, ateroesclerosis, resistencia a la insulina y síndrome X, diabetes mellitus tipo 2, obesidad, nefropatía, insuficiencia renal, hipotiroidismo, sobrevivencia posterior a infarto al miocardio, enfermedades cardíacas coronarias, hipertension en la ancianidad, hipertension dislipidérmica familiar, y remodelacion enseguida de hipertension (efecto antiproliferativo de la combinacion), todas estas enfermedades o condiciones asociadas con o sin hipertension, para la prevencion, demora de progreso o tratamiento de embolia, disfuncion eréctil, y enfermedad vascular para la fabricacion de un medicamento, un agente terapéutico, y una composicion farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19674300P | 2000-04-12 | 2000-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032152A1 true AR032152A1 (es) | 2003-10-29 |
Family
ID=22726659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101697A AR032152A1 (es) | 2000-04-12 | 2001-04-10 | Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040023840A1 (es) |
| EP (1) | EP1326604A2 (es) |
| JP (1) | JP2003530342A (es) |
| KR (1) | KR20020089433A (es) |
| CN (2) | CN1440283A (es) |
| AR (1) | AR032152A1 (es) |
| AU (1) | AU2001258323A1 (es) |
| BR (1) | BR0109966A (es) |
| CA (1) | CA2405793A1 (es) |
| CZ (1) | CZ20023381A3 (es) |
| HU (1) | HUP0400475A3 (es) |
| IL (1) | IL152079A0 (es) |
| MX (1) | MXPA02010090A (es) |
| NO (1) | NO20024921L (es) |
| PE (1) | PE20020229A1 (es) |
| PL (1) | PL365696A1 (es) |
| RU (1) | RU2298418C2 (es) |
| SK (1) | SK14642002A3 (es) |
| WO (1) | WO2001076573A2 (es) |
| ZA (1) | ZA200208203B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1216038T3 (da) | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| NZ522953A (en) * | 2000-06-22 | 2005-10-28 | Novartis Ag | Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| WO2002085363A1 (en) * | 2001-04-19 | 2002-10-31 | Kowa Co., Ltd. | Remedial agent for glomerular disease |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| MXPA04004844A (es) * | 2001-11-23 | 2004-07-30 | Solvay Pharm Gmbh | Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular. |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| KR101092279B1 (ko) * | 2002-12-27 | 2011-12-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 체중 증가 억제제 |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| PL376213A1 (en) * | 2003-01-16 | 2005-12-27 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| ES2421520T3 (es) * | 2003-04-28 | 2013-09-03 | Daiichi Sankyo Co Ltd | Potenciador de la producción de adiponectina |
| AU2004233691B2 (en) * | 2003-04-28 | 2007-09-20 | Sankyo Company, Limited | Sugar intake-ability enhancer |
| RS20060018A (sr) | 2003-07-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja |
| GB0322552D0 (en) * | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| AU2008201290B2 (en) * | 2003-09-26 | 2010-12-09 | Astrazeneca Uk Limited | Therapeutic treatment |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| CN1889948A (zh) * | 2003-12-16 | 2007-01-03 | 诺瓦提斯公司 | 他汀用于治疗代谢综合征的用途 |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| JPWO2006046528A1 (ja) * | 2004-10-29 | 2008-05-22 | 興和株式会社 | 糸球体疾患治療剤 |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| US8685952B2 (en) | 2006-01-31 | 2014-04-01 | Kowa Co., Ltd. | Method for the treatment of diabetes |
| KR101436644B1 (ko) * | 2006-01-31 | 2014-09-01 | 코와 가부시키가이샤 | 당뇨병 치료제 |
| FR2911279B1 (fr) * | 2007-01-11 | 2009-03-06 | Servier Lab | Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale |
| GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
| RU2393857C2 (ru) * | 2008-05-12 | 2010-07-10 | Государственное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию | Лекарственное средство, оказывающее противосудорожное и антигипоксическое действие |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| RU2505297C1 (ru) * | 2012-11-21 | 2014-01-27 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | Средство для медикаментозной коррекции нарушений нитроксидергической системы |
| HRP20171231T1 (hr) * | 2013-05-13 | 2017-10-20 | Macro Plastics, Inc. | Transportni spremnik sa sigurnosnom bravom |
| BR102013028883A2 (pt) * | 2013-11-08 | 2015-10-06 | Hypermarcas S A | forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica |
| MD4412C1 (ro) * | 2014-08-29 | 2016-11-30 | Алёна ДУРНЯ | Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| EA034975B1 (ru) * | 2018-03-13 | 2020-04-13 | Владимир Александрович Горшков-Кантакузен | Способ лечения лабильной и пароксизмальной гипертензии |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981470A (en) * | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
| CZ313897A3 (cs) * | 1995-04-07 | 1998-01-14 | Novartis Ag | Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan |
| JPH11508894A (ja) * | 1995-06-30 | 1999-08-03 | メルク エンド カンパニー インコーポレーテッド | Ace阻害剤とaii拮抗薬を用いる腎疾患の治療方法 |
| BR9708336A (pt) * | 1996-03-29 | 1999-08-03 | Smithkline Beecham Corp | Diidrato de eprosartan e processo para sua produção e formulação |
| DE69731840T2 (de) * | 1996-07-15 | 2005-08-04 | Sankyo Co., Ltd. | Pharmazeutische Zusammensetzungen enthaltend CS-866 und Insulinresistenz verbessernde Mittel und deren Verwendung zur Behandlung von Arteriosklerose und Xanthom |
-
2001
- 2001-04-10 CN CN01807919A patent/CN1440283A/zh active Pending
- 2001-04-10 WO PCT/EP2001/004115 patent/WO2001076573A2/en not_active Ceased
- 2001-04-10 BR BR0109966-3A patent/BR0109966A/pt not_active IP Right Cessation
- 2001-04-10 AR ARP010101697A patent/AR032152A1/es not_active Application Discontinuation
- 2001-04-10 CA CA002405793A patent/CA2405793A1/en not_active Abandoned
- 2001-04-10 RU RU2002129558/15A patent/RU2298418C2/ru not_active IP Right Cessation
- 2001-04-10 IL IL15207901A patent/IL152079A0/xx unknown
- 2001-04-10 SK SK1464-2002A patent/SK14642002A3/sk unknown
- 2001-04-10 CN CNA2004101012182A patent/CN1651087A/zh active Pending
- 2001-04-10 KR KR1020027013336A patent/KR20020089433A/ko not_active Ceased
- 2001-04-10 EP EP01931583A patent/EP1326604A2/en not_active Withdrawn
- 2001-04-10 AU AU2001258323A patent/AU2001258323A1/en not_active Abandoned
- 2001-04-10 JP JP2001574091A patent/JP2003530342A/ja active Pending
- 2001-04-10 PL PL01365696A patent/PL365696A1/xx not_active Application Discontinuation
- 2001-04-10 MX MXPA02010090A patent/MXPA02010090A/es active IP Right Grant
- 2001-04-10 CZ CZ20023381A patent/CZ20023381A3/cs unknown
- 2001-04-10 US US10/257,559 patent/US20040023840A1/en not_active Abandoned
- 2001-04-10 HU HU0400475A patent/HUP0400475A3/hu unknown
- 2001-04-10 PE PE2001000327A patent/PE20020229A1/es not_active Application Discontinuation
-
2002
- 2002-10-11 ZA ZA200208203A patent/ZA200208203B/en unknown
- 2002-10-11 NO NO20024921A patent/NO20024921L/no not_active Application Discontinuation
-
2006
- 2006-10-31 US US11/590,215 patent/US20070105894A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0109966A (pt) | 2003-08-05 |
| WO2001076573A2 (en) | 2001-10-18 |
| KR20020089433A (ko) | 2002-11-29 |
| PL365696A1 (en) | 2005-01-10 |
| SK14642002A3 (sk) | 2003-05-02 |
| CZ20023381A3 (cs) | 2003-02-12 |
| PE20020229A1 (es) | 2002-04-11 |
| MXPA02010090A (es) | 2003-02-12 |
| RU2298418C2 (ru) | 2007-05-10 |
| HUP0400475A2 (hu) | 2004-06-28 |
| AU2001258323A1 (en) | 2001-10-23 |
| WO2001076573A3 (en) | 2003-04-17 |
| NO20024921L (no) | 2002-11-07 |
| CA2405793A1 (en) | 2001-10-18 |
| EP1326604A2 (en) | 2003-07-16 |
| ZA200208203B (en) | 2003-11-07 |
| CN1651087A (zh) | 2005-08-10 |
| CN1440283A (zh) | 2003-09-03 |
| JP2003530342A (ja) | 2003-10-14 |
| NO20024921D0 (no) | 2002-10-11 |
| HUP0400475A3 (en) | 2006-02-28 |
| US20070105894A1 (en) | 2007-05-10 |
| IL152079A0 (en) | 2003-05-29 |
| US20040023840A1 (en) | 2004-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032152A1 (es) | Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica | |
| AR032316A1 (es) | Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica | |
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| WO1995014384A1 (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
| JP2019112409A (ja) | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 | |
| AR005281A1 (es) | Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. . | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| AR018582A1 (es) | Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentos | |
| RU2002105377A (ru) | Ксенон-антагонист nmda | |
| KR20070072502A (ko) | 관절 류머티즘의 예방 및/또는 치료약 | |
| AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
| ES2840079T3 (es) | Composición farmacéutica para el tratamiento de la esteatosis hepática no alcohólica | |
| PE20040973A1 (es) | Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroidales | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| Gaudilliere et al. | To market, to market—2000 | |
| US20230277523A1 (en) | Methods for inhibiting phosphate transport | |
| AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
| ES2525931T3 (es) | Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal | |
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| AR038858A1 (es) | Combinacion | |
| Hsu et al. | Pharmacotherapy for obesity: past, present and future | |
| AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |